Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease
Abstract Peptide therapeutics are increasingly used in the treatment of disease, but their administration by injection reduces patient compliance and convenience, especially for chronic diseases. Thus, oral administration of a peptide therapeutic represents a significant advance in medicine, but is...
Saved in:
Main Authors: | Sergei Pechenov, Jefferson Revell, Sarah Will, Jacqueline Naylor, Puneet Tyagi, Chandresh Patel, Lihuan Liang, Leo Tseng, Yue Huang, Anton I. Rosenbaum, Kemal Balic, Anish Konkar, Joseph Grimsby, J. Anand Subramony |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/3ba0d823dad649b18d617f5537b9b8f7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting GLP-1 receptor trafficking to improve agonist efficacy
by: Ben Jones, et al.
Published: (2018) -
Role and development of GLP-1 receptor agonists in the management of diabetes
by: Chee W Chia, et al.
Published: (2009) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Neff LM
Published: (2010) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Lisa M Neff, et al.
Published: (2010) -
Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
by: Mette Simone Aae Madsen, et al.
Published: (2019)